Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Understanding the role of obesity in endocrine therapy for postmenopausal breast cancer : significance of the BIG 1–98 and ATAC trial data

Harborg, Sixten and Borgquist, Signe LU (2025) In Discover Oncology 16(1).
Abstract

Obesity is a known risk factor for poor breast cancer outcomes, but its impact on endocrine therapy efficacy remains unclear. While the ATAC trial suggests reduced effectiveness of aromatase inhibitors (AIs) in women with obesity, the BIG 1–98 trial found no significant differences. Clinical and biological evidence indicates that obesity may impair AI efficacy by increasing aromatase activity and altering drug metabolism, whereas tamoxifen remains largely unaffected. Pooling data from these trials would enable detailed analyses across body composition categories, addressing discrepancies and potentially guide personalized treatment strategies. Understanding the interaction between obesity and endocrine therapy is crucial for optimizing... (More)

Obesity is a known risk factor for poor breast cancer outcomes, but its impact on endocrine therapy efficacy remains unclear. While the ATAC trial suggests reduced effectiveness of aromatase inhibitors (AIs) in women with obesity, the BIG 1–98 trial found no significant differences. Clinical and biological evidence indicates that obesity may impair AI efficacy by increasing aromatase activity and altering drug metabolism, whereas tamoxifen remains largely unaffected. Pooling data from these trials would enable detailed analyses across body composition categories, addressing discrepancies and potentially guide personalized treatment strategies. Understanding the interaction between obesity and endocrine therapy is crucial for optimizing breast cancer care.

(Less)
Please use this url to cite or link to this publication:
author
and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Discover Oncology
volume
16
issue
1
article number
1233
publisher
Springer Science and Business Media B.V.
external identifiers
  • pmid:40591100
  • scopus:105009887037
DOI
10.1007/s12672-025-02857-w
language
English
LU publication?
yes
id
e13c654b-1028-48fc-922e-d0eb8c6558ca
date added to LUP
2025-10-24 15:02:30
date last changed
2025-10-25 03:00:01
@article{e13c654b-1028-48fc-922e-d0eb8c6558ca,
  abstract     = {{<p>Obesity is a known risk factor for poor breast cancer outcomes, but its impact on endocrine therapy efficacy remains unclear. While the ATAC trial suggests reduced effectiveness of aromatase inhibitors (AIs) in women with obesity, the BIG 1–98 trial found no significant differences. Clinical and biological evidence indicates that obesity may impair AI efficacy by increasing aromatase activity and altering drug metabolism, whereas tamoxifen remains largely unaffected. Pooling data from these trials would enable detailed analyses across body composition categories, addressing discrepancies and potentially guide personalized treatment strategies. Understanding the interaction between obesity and endocrine therapy is crucial for optimizing breast cancer care.</p>}},
  author       = {{Harborg, Sixten and Borgquist, Signe}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{Springer Science and Business Media B.V.}},
  series       = {{Discover Oncology}},
  title        = {{Understanding the role of obesity in endocrine therapy for postmenopausal breast cancer : significance of the BIG 1–98 and ATAC trial data}},
  url          = {{http://dx.doi.org/10.1007/s12672-025-02857-w}},
  doi          = {{10.1007/s12672-025-02857-w}},
  volume       = {{16}},
  year         = {{2025}},
}